519 related articles for article (PubMed ID: 25818660)
21. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
23. Our 2014 approach to candidaemia.
Koehler P; Tacke D; Cornely OA
Mycoses; 2014 Oct; 57(10):581-3. PubMed ID: 24863378
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.
Shah DN; Yau R; Weston J; Lasco TM; Salazar M; Palmer HR; Garey KW
J Antimicrob Chemother; 2011 Sep; 66(9):2146-51. PubMed ID: 21700622
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
[TBL] [Abstract][Full Text] [Related]
26. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
[TBL] [Abstract][Full Text] [Related]
27. Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes.
Lai MY; Hsu JF; Chu SM; Wu IH; Huang HR; Lin CC; Lee IT; Chiang MC; Fu RH; Tsai MH
Future Microbiol; 2017 Jun; 12():695-705. PubMed ID: 28326813
[TBL] [Abstract][Full Text] [Related]
28. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
Wade RL; Chaudhari P; Campbell RS; Hays HD; Nathanson BH; Yi J; Horn D
J Med Econ; 2012; 15(6):1130-8. PubMed ID: 22788668
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study.
Aguilar G; Delgado C; Corrales I; Izquierdo A; Gracia E; Moreno T; Romero E; Ferrando C; Carbonell JA; Borrás R; Navarro D; Belda FJ
BMC Res Notes; 2015 Sep; 8():491. PubMed ID: 26415526
[TBL] [Abstract][Full Text] [Related]
30. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
[TBL] [Abstract][Full Text] [Related]
32. Candidemia in children.
Zaoutis T
Curr Med Res Opin; 2010 Jul; 26(7):1761-8. PubMed ID: 20513207
[TBL] [Abstract][Full Text] [Related]
33. Antifungals in the ICU.
Playford EG; Eggimann P; Calandra T
Curr Opin Infect Dis; 2008 Dec; 21(6):610-9. PubMed ID: 18978529
[TBL] [Abstract][Full Text] [Related]
34. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
[TBL] [Abstract][Full Text] [Related]
35. Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility.
Nieto MC; Tellería O; Cisterna R
Diagn Microbiol Infect Dis; 2015 Jan; 81(1):34-40. PubMed ID: 25439581
[TBL] [Abstract][Full Text] [Related]
36. Invasive Candidiasis.
Gonzalez-Lara MF; Ostrosky-Zeichner L
Semin Respir Crit Care Med; 2020 Feb; 41(1):3-12. PubMed ID: 32000280
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.
Pfaller MA; Andes DR; Diekema DJ; Horn DL; Reboli AC; Rotstein C; Franks B; Azie NE
PLoS One; 2014; 9(7):e101510. PubMed ID: 24991967
[TBL] [Abstract][Full Text] [Related]
38. Anidulafungin for the treatment of invasive candidiasis.
Mayr A; Aigner M; Lass-Flörl C
Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
[TBL] [Abstract][Full Text] [Related]
39. Candidemia and invasive candidiasis: a review of the literature for the burns surgeon.
Ha JF; Italiano CM; Heath CH; Shih S; Rea S; Wood FM
Burns; 2011 Mar; 37(2):181-95. PubMed ID: 20395056
[TBL] [Abstract][Full Text] [Related]
40. Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
Perkhofer S; Hell M; Gustorff B; Von Goedecke A; Illievich U; Kratzer C; Moosbauer W; Wimmer P; Zerlauth U; Nachbaur K; Vogel W; Bellmann R; Schwameis F; Lass-Flörl C
J Chemother; 2011 Oct; 23(5):285-9. PubMed ID: 22005061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
